Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China

BACKGROUND AND OBJECTIVE: Teriflunomide is a once-daily oral immunomodulatory agent approved in 80 countries for the treatment of patients with relapsing multiple sclerosis (RMS). The study objective was to estimate the cost effectiveness of teriflunomide (14 mg tablet, daily) versus interferon beta...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yan, Mao, Ningying, Chirikov, Viktor, Du, Fen, Yeh, Yu-Chen, Liu, Li, Liu, Ruiqi, Gao, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400872/
https://www.ncbi.nlm.nih.gov/pubmed/30684251
http://dx.doi.org/10.1007/s40261-019-00750-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400872/
https://www.ncbi.nlm.nih.gov/pubmed/30684251
http://dx.doi.org/10.1007/s40261-019-00750-3

Ejemplares similares